English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

during induction, followed by placebo maintenance; and 3) CP plus concurrent bevacizumab during induction, followed by bevacizumab maintenance. Bevacizumab was not administered during the first 21-day induction cycle so as to limit post- surgical bleeding complications. The entire treatment sched- ule took 15 months to complete. Although overall survival was originally selected as the primary endpoint, this was changed to progression-free survival (PFS) to accord with international consensus as a more appropriate endpoint for frontline phase III trials in this patient population, as well as pressure by pa- tients to unblind their treatment assignment in the event of disease progression. The investigators monitored disease pro- gression based on radiographic evidence, CA-125 measure- ments, and global clinical deterioration. Overall survival, safe- ty, and quality of life comprised the secondary endpoints.

Evolving strategies for ovarian cancer: gynecologic oncology in ASCO's 46th annual meeting